Blood particles may reveal hidden clues to scleroderma complications
NCT ID NCT07717060
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study looks at how tiny particles called extracellular vesicles travel through the bloodstream in people with systemic sclerosis, an autoimmune disease that affects blood vessels and organs. Researchers will take blood samples from different points in the circulation to see if differences in these particles can predict serious problems like pulmonary hypertension and digital ulcers. The goal is to find new ways to identify patients at higher risk and better understand how the disease spreads through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could identify new biomarkers to predict serious complications like pulmonary hypertension and digital ulcers in systemic sclerosis patients.
- What could go wrong
- This is an observational study with only 60 participants, so findings may not apply to all patients. It aims to understand disease mechanisms rather than test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIGITAL ULCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Heart procedure showdown: serpentine twist vs. guidewire for navigating artery curves
- Heart scans may soon replace Needle-Based catheter tests
- Could a new drug free PAH patients from daily pump therapy?
- Finger injections aim to loosen stiff hands in scleroderma
- Continued anifrolumab treatment studied for lupus and related diseases